ESTRO 2024 - Abstract Book

S4836

Physics - Quality assurance and auditing

ESTRO 2024

Conclusion:

Nationally, breast MHD is well below 2Gy in both left and right breast 26Gy/5# plans. Further work is required to standardise breast PTV nomenclature and definition. For Lung SABR patients nationally, over all dose regimes, PTV coverage was acceptable for >80% of patients, and both Heart 0.5cc dose and Spinal Canal 0.1cc dose were shown to